Macrodantin

Nitrofurantoin, the active ingredient in Macrodantin, is a nitrofuran antibiotic presented as an oral tablet for oral administration. It is indicated for the treatment of uncomplicated urinary tract infections, primarily in adult patients with susceptible bacterial strains.

GNH USA supplies Macrodantin as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide with consistent quality and regulatory compliance. The product conforms to European Union pharmacopeial standards and is manufactured under GMP conditions. It is distributed through GNH USA's global logistics network ensuring timely delivery.

Macrodantin (nitrofurantoin) is used to treat infections of the urinary tract caused by susceptible bacteria.

Uncomplicated urinary tract infection: eradicates the causative bacteria, relieving symptoms and preventing recurrence. Acute uncomplicated cystitis: provides rapid bacterial clearance in bladder infection. Prevention of recurrent urinary tract infection: reduces incidence when taken as a low‑dose prophylactic regimen.

Nitrofurantoin may cause a range of adverse reactions. Patients should be informed of common and serious possibilities.

Common Side Effects: - Nausea or upset stomach - Loss of appetite - Headache - Diarrhea or loose stools - Metallic taste in the mouth - Mild skin rash or itching

Serious or Rare Side Effects: - Pulmonary toxicity (interstitial pneumonitis or fibrosis) - Hepatic injury (elevated liver enzymes, hepatitis) - Severe allergic reactions, including anaphylaxis - Hemolytic anemia in individuals with G6PD deficiency - Peripheral neuropathy - Severe cutaneous reactions such as Stevens‑Johnson syndrome

Before prescribing Macrodantin, clinicians should consider several safety factors. - Renal function: assess creatinine clearance and avoid use in patients with markedly reduced renal function. - Pregnancy: avoid unless the expected benefit outweighs potential risk to the fetus. - Breastfeeding: evaluate risk of drug excretion in milk and possible infant exposure. - G6PD deficiency: contraindicated due to risk of hemolysis. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in the original packaging, protect from moisture and heat.

Nitrofurantoin can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: significantly decrease nitrofurantoin absorption. - Probenecid: may raise nitrofurantoin plasma levels, increasing toxicity risk. - Ceftriaxone: can increase the likelihood of crystalluria.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect; monitor INR regularly. - Fluoroquinolones: additive risk of tendonitis or tendon rupture. - Diuretics: may enhance risk of crystalluria; ensure adequate hydration.